| 乳腺癌表皮生长因子受体-2分子靶向治疗临床应用策略 |
| |
| 引用本文： | 江泽飞,边莉.乳腺癌表皮生长因子受体-2分子靶向治疗临床应用策略[J].中华普外科手术学杂志（电子版）,2011,5(4):10-14. |
| |
| 作者姓名： | 江泽飞 边莉 |
| |
| 作者单位： | 军事医学科学院附属医院乳腺肿瘤科,北京,100071 |
| |
| 摘 要： | 乳腺癌分子靶向治疗显著改善了人表皮生长因子受体-2（HER-2）阳性患者的疗效,本文总结了HER-2靶向治疗中若干临床应用策略,包括复发转移乳腺癌患者转移病灶需要重活检进行HER-2重检测;曲妥珠单抗治疗进展后继续应用或者换用拉帕替尼均可获益;乳腺癌临床实践指南（NCCN）推荐HER-2阳性大于1cm肿瘤辅助化疗同时联合曲妥珠单抗治疗,目前曲妥珠单抗标准治疗时间为1年;目前NCCN不推荐新辅助采取双重靶向药物治疗;在HER-2阳性乳腺癌新辅助、辅助、复发转移治疗阶段,均可能产生靶向治疗耐药,区分为原发耐药与继发耐药;在临床实践中建议根据患者耐药类型选择后续靶向治疗,同时需要继续寻找耐药相关生物学指标,预测耐药的发生,从而使患者从分子靶向治疗中最大程度获益。
|
| 关 键 词： | 乳腺肿瘤 受体 表皮生长因子 肿瘤治疗方案 分子靶向治疗 |
Clinical application of HER-2 targeted therapy in patients with breast cancer |
| |
| Authors: | JIANG Ze-fei BIAN Li |
| |
| Institution: | JIANG Ze-fei,BIAN Li.Department of Breast Cancer,Affiliated Hospital of Academy of Military Medical Sciences,Beijing 100071,China |
| |
| Abstract: | Molecular targeted therapy of breast cancer greatly improved the therapeutic effect of HER-2(human epidermal growth factor receptor-2) positive breast cancer.This study described several clinical applications in HER-2 targeted therapy,including recurrent or metastatic breast cancer needing re-biopsy for HER-2 detection.Patients could benefit from keeping using trastuzumab or changing to lapatinib even cancer progressed during trastuzumab treatment.As the NCCN guidelines recommend,patients with HER-2 positiv... |
| |
| Keywords: | Breast neoplasms Receptor epidermal growth factor Antineoplastic protocols Molecular targeted therapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
